JP Morgan analyst Alexia Quadrani downgrades Roblox (NYSE:RBLX) from Overweight to Neutral and lowers the price target from $53 to $35.
Bristol Myers Squibb’s Acquired Adagrasib Combo Therapy May Benefit Colorectal Cancer Patients With Certain Mutation
Bristol Myers Squibb's latest data on Krazati (adagrasib) in combination with cetuximab for KRASG12C-mutated colorectal cancer. Promising objective response rates and progression-free survival. FDA priority review underway.
